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Abstract 
Background: The beneficial effects of polyphenols have been reported. This study aimed to investigate the effect of 
oral Ellagic acid (EA) supplement on insulin resistance (IR) and Fetuin-A and serum sirtuin1 (SIRT1) in type 2 diabetics.
Methods: In this double-blind, randomized clinical trial, 44 diabetic patients were selected. Patients were assigned to 
the intervention group (22 subjects) and placebo (22 subjects) and received a capsule containing 180 mg of EA per 
day or placebo for eight weeks, respectively. At the beginning and end of the study, anthropometric indices, fasting 
plasma glucose (FPG), plasma insulin level, IR, Fetuin-A, and SIRT1 were measured. Statistical analysis was performed 
using SPSS software.
Results: At the beginning and end of the study, there was no significant difference between the two groups regard-
ing anthropometric indices (P > 0.05). At the end of the survey, EA supplementation significantly reduced FPG, insulin, 
IR, and Fetuin-A and increased SIRT1 levels compared with the placebo group (P < 0.05). However, these changes were 
not significant in the placebo group (P > 0.05).
Conclusion: EA with antioxidant properties plays an essential role in reducing the macrovascular and microvascular 
complications of diabetes by reducing inflammation and insulin resistance.
Trial registration The protocol of this clinical trial is registered with the Iranian Registry of Clinical Trials (http://www.
IRCT.IR, identifier: IRCT20141025019669N13)
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Background
Diabetes mellitus is one of the five leading causes of death 
in the world, characterized by impaired insulin secretion, 
insulin activity, or both, and is divided into two catego-
ries: type 1 diabetes and type 2 diabetes [1]. Results of 
studies show that in 2030, 552 million people will have 
type 2 diabetes. Insulin function in diabetics and its sub-
sequent resistance or sensitivity to insulin are the cases 
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